BridgeBio Pharma, Inc. (BBIO) Financials
BBIO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 1.2 billion | 3.7 billion |
| March 31, 2026 | 1.4 billion | 3.6 billion |
| Dec. 31, 2025 | 936.0 million | 3.0 billion |
| Sept. 30, 2025 | 998.3 million | 2.9 billion |
BBIO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -223.8 million | 44.1 million |
| March 31, 2026 | -197.3 million | 33.2 million |
| Dec. 31, 2025 | -61.0 million | 34.6 million |
| Sept. 30, 2025 | -110.0 million | 35.3 million |
BBIO Net Income
No data available :(
BBIO Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 720.2 million | 1.9 billion | 18.3 million |
| March 31, 2026 | 940.2 million | 2.8 billion | 14.2 million |
| Dec. 31, 2025 | 587.5 million | 2.7 billion | 3.8 million |
| Sept. 30, 2025 | 645.9 million | 1.9 billion | 8.7 million |
BBIO Shares Outstanding
BBIO Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 443000 | 149.4 million | 186.3 million | - |
| March 31, 2026 | 69000 | 126.6 million | 163.9 million | - |
| Dec. 31, 2025 | 4.5 million | 142.0 million | 182.0 million | - |
| Sept. 30, 2025 | 470000 | 112.9 million | 137.6 million | - |
BBIO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 222.4 million | 15.0 million |
| March 31, 2026 | 194.5 million | 10.4 million |
| Dec. 31, 2025 | 154.2 million | 15.4 million |
| Sept. 30, 2025 | 120.7 million | 6.6 million |
BBIO Revenue by Segment
Graph available only for paid members. Upgrade to see it.
BBIO
Price: $79.86
52 week price:
Payout Ratio Range:
Earnings Per Share: -3.56 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.7 million
Market Capitalization: 16.4 billion